Jubilant Of India Thrives In CRAMS Market Dwindling For Others
This article was originally published in PharmAsia News
Executive Summary
India's Jubilant Organosys has good financial prospects thanks to its focus on CRAMS work for the pharmaceutical and biotechnology sectors. The outlook for the company is strong despite a large debt, mainly because it is expected to double its revenue and earnings in both sectors. The company expects to continue to profit from outsourcing activity as global pharmaceuticals face cost pressures and Western governments work to reduce health care costs. Jubilant also has fared better than Indian competitors that have faced a slowdown in outsourcing clients. (Click here for more